Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2022 | ZUMA-3: impact of prior blinatumomab and alloSCT

Bijal Shah • 4 Jun 2022
ASCO 2022
Acute Lymphoblastic Leukemia Leukemia Antibodies Blinatumomab Brexucabtagene autoleucel CAR-T Fludarabine
ZUMA-3

Bijal Shah, MD, Moffitt Cancer Center, Tampa, FL, provides an overview on the use of brexucabtagene autoleucel (brexu-cel) in patients treated with prior blinatumomab therapy, highlighting the poorer overall survival that was observed. Dr Shah also discusses the role of allogeneic stem cell transplantation (alloSCT) in this setting. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

More from Bijal Shah

1:33
The impact of prior therapies on the outcomes of patients with R/R ALL treated with CAR-T therapy
Bijal Shah • 8 Sep 2023
1:27
TP53-aberrant MCL: challenges and treatment approaches
Bijal Shah • 8 Sep 2023
1:03
ECOG-E1910 study: clinical benefit of early blinatumomab incorporation in ALL
Bijal Shah • 8 Sep 2023
1:03
An insight into the sequencing of immunotherapies in adults with ALL
Bijal Shah • 8 Sep 2023

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals